Current role of surgery and multimodal treatment in localized gastric cancer

Annals of Oncology

Volumn 19, Issue SUPPL. 5, 2008, Pages

  Van de velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; OTERACIL POTASSIUM; POTASSIUM DERIVATIVE; TEGAFUR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANOREXIA; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; GASTRECTOMY; HEART INFARCTION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREAS RESECTION; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SPLENECTOMY; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; LYMPHADENECTOMY; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 49049098523     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn319     Document Type: Conference Paper

References (53)

1. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982; 8: 1 -11.
2. Landry J, Tepper JE, Wood WC et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990; 19: 1357-1362.
3. Jansen E, Boot H, Verheij M et al. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005; 23: 4509-4517.
4. Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-2077.
5. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
6. van de Velde CJ, Peeters KC. The gastric cancer treatment controversy. J Clin Oncol 2003; 21: 2234-2236.
7. Petrelli NJ. The debate is over; it's time to move on. J Clin Oncol 2004; 22: 2041-2042.
8. Sobin LH, Wittekind C. International Union Against Cancer: TNM classification of malignant tumors. New York: Wiley-Liss, 1997.
9. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75(2): 110-112.
10. Robertson CS, Chung SC, Woods SD et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994; 220: 176-182.
11. Bonenkamp JJ, van de Velde CJ, Kampschoer GH et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg 1993; 17: 410-414.
12. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Cooperative group. Br J Cancer 1999; 79: 1522-1530.
13. Sasako M, Sano T, Yamamoto S, Nashimoto A et al. Randomized phase III trial of standard D2 versus D2 + para-aortic lymph node (PAN) dissection (D) for clinically MO advanced gastric cancer. ASCO Annual Meeting Proc. J Clin Oncol 2006; 24 (Suppl 20): 18S.
14. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: A randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
15. Maruyama K. The most important prognostic factors for gastric cancer patients: A study using univariate and multivariate analysis. Scand J Gastroenterol 1987; 22 (Suppl 133): 63-68.
16. Peeters KC, Hundahl SA, Kranenbarg EK et al. Low Maruyama index surgery for gastric cancer: Blinded reanalysis of the Dutch D1-D2 trial. World J Surg 2005; 29: 1576-1584.
17. Peeters KC, Kattan MW, Hartgrink HH et al. Validation of a nomogram for predicting disease-specific survival after an RO resection for gastric carcinoma. Cancer 2005; 103: 702-707.
18. Kitagawa Y, Fujii H, Kumai K et al. Recent advances in sentinel node navigation for gastric cancer: A paradigm shift of surgical management. J Surg Oncol (Semin) 2005; 90: 147-152.
19. Lynch HT, Grady W, Suriano G et al. Gastric cancer: New genetic developments. J Surg Oncol (Semin) 2005; 90: 114-133.
20. Hallissey MT, Dunn JA, Ward LC et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up. Lancet 1994; 343: 1309-1312.
21. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059-1064.
22. Gianni L, Panzini I, Tassinari D et al. Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol 2001; 12: 1178-1180.
23. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447.
24. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002; 168: 597-608.
25. Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837-843.
26. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy in operable gastric cancer and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2005: 308s.
27. Cochrane Library 2005.
28. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
29. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
30. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
31. Evans TR, Pentheroudakis G, Paul J et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 2002; 13: 1469-1478.
32. Cho EK, Lee WK, Im SA et al. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 2005; 68: 333-340.
33. Cunningham D, Rao S, Starling N et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol 2006; 24: 18s (Abstr LBA4017).
34. Sasako M, Yamaguchi T, Kinoshita T at al. Randomized phase III trial comparing S-1 montherapy versus surgery alone for stage II/III gastric cancer patients (pts) after curative D2 gastrectomy (ACTS-GC study). Gastrointestinal Cancers Symposium, Orlando, FL, January 19-21, 2007.
35. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal juncton. N Engl J Med 2001; 345: 725-730.
36. Hundahl SA, Macdonald JS, Benedetti J et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Ann Surg Oncol 2002; 9: 278-286.
37. al Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 1997; 15: 277-284.
38. Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049.
39. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
40. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144-1153.
41. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-530.
42. Byfield JE, Calabro-Jones P, Klisak I et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radial Oncol Biol Phys 1982; 8: 1923-1933.
43. Kjellstrom J, Kjellen E, Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 2005; 44: 687-693.
44. Rodel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
45. Vaishampayan UN, Ben Josef E, Philip PA et al. A single-instituition experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2002; 253: 675-679.
46. Kollmannsberger C, Budach W, Stahl M et al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: Two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol 2005; 16: 1326-1333.
47. Jansen.
48. Dewit L, Anninga JK, Hoefnagel CA et al. Radiation injury in the human kidney: A prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys 1990; 19: 977-983.
49. Verheij.
50. Kattan MW, Karpeh MS, Mazumdar M et al. Postoperative nomogram for disease-specific survival after an RO resection for gastric carcinoma. J Clin Oncol 2003; 21: 3647-3650.
51. Maruyama K, Gunven P, Okabayashi K et al. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 1989; 210: 596-602.
52. Peeters KC, Kattan MW, Hartgrink HH et al. Validation of a nomogram for predicting disease-specific survival after an RO resection for gastric carcinoma. Cancer 2005; 103: 702-707.
53. Peeters KC, Hundahl SA, Kranenbarg EK et al. Low Maruyama index surgery for gastric cancer: Blinded reanalysis of the Dutch D1-D2 trial. World J Sung 2005; 29: 1576-1584.